Photo Credit: Gulyayeva
The following is a summary of “FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.
Researchers conducted a retrospective study to evaluate the efficacy of JNJ-77242113, a targeted oral peptide inhibiting interleukin (IL) -23 receptor signaling, in patients with moderate-to-severe plaque psoriasis over 1 year in the FRONTIER-2 extension of the phase 2 FRONTIER-1 study.
They enrolled participants in the FRONTIER-1 study who received JNJ-77242113 at doses ranging from 25mg once daily (QD) to 100mg twice daily (BID) or a placebo up to W16. Patients who completed FRONTIER-1 were eligible to enroll in FRONTIER-2, where they continued JNJ-77242113 at the same dose through W52 and ones initially on placebo switched to JNJ-77242113 100mg QD between W16 and W52 and conducted the Safety monitoring through W56.
The results showed that 89% of FRONTIER-1 patients continued to FRONTIER-2. The response rates were maintained from W16 to W52 across outcomes with the highest response rates were observed with JNJ-77242113 100mg BID. At W52, 76% of patients achieved Psoriasis Area and Severity Index (PASI75) with 100mg BID; rates were 64% for PASI90, 74% for Investigator’s Global Assessment (IGA)0/1, 40% for PASI100, and 43% for IGA0, from W16 to W56, 59% of patients treated with JNJ-77242113 had ≥1 adverse events (AE) while, Serious AEs, considered unrelated to treatment, occurred in 4% of patients.
Investigators concluded that JNJ-77242113 demonstrated durable skin clearance rates for up to a year, with no new safety signals.
Source: jaad.org/article/S0190-9622(24)03152-9/abstract
